Read More

Reported Saturday, 4DMT Presented Injection-Free Subgroup Analyses From 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort In Wet AMD Patients With Severe Disease Activity & High Treatment Burden At The Clinical Trials Summit 2024

Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher than in the

FDMT